Empty nose syndrome

Summary

Empty nose syndrome (MONDO:1060148) is a disease and 3 clinical trials. Top therapeutic interventions include botulinum toxin type a. A subtype of atrophic rhinitis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 3

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	empty nose syndrome
Mondo ID	MONDO:1060148
UMLS	C3888849
MedGen	1876481
GARD	0028165
Is cancer (heuristic)	no

Also known as: ENS · nasal iatrogenic dysfunction · post-turbinectomy syndrome · secondary atrophic rhinitis

Disease family

This is a subtype of atrophic rhinitis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › otorhinolaryngologic disease › nasal disorder › nasal cavity disorder › rhinitis › atrophic rhinitis › empty nose syndrome

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 3.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	2
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00732680	PHASE1/PHASE2	TERMINATED	Benefits of the Use of Botox in the Treatment of Empty Nose Syndrome Syndrome
NCT07215013	Not specified	NOT_YET_RECRUITING	Acoustic Resonance Therapy for Treating Empty Nose Syndrome
NCT02230423	Not specified	COMPLETED	Trigeminal Endonasal Perception: A Predictor for Septoplasty Outcome

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
BOTULINUM TOXIN TYPE A	4	1